Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Federica Zoratto, Luigi Rossi, Angelo Zullo, Anselmo Papa, Eleonora Zaccarelli, Luigi Tomao, Erika Giordani, Maria Colonna, Giovanni Baiano & Silverio Tomao. (2012) Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. OncoTargets and Therapy 5, pages 199-211.
Read now
Read now
Articles from other publishers (12)
Fatemeh Heidari, Soheil Madadi, Neda Alizadeh, Mohammad Hossein Alimardani, Armin Safari, Mohammad Hossein Armand, Elahe Pishgahzadeh & Meysam Soleimani. (2023) The potential of monoclonal antibodies for colorectal cancer therapy. Medical Oncology 40:9.
Crossref
Crossref
Surya K. De. 2022. Fundamentals of Cancer Detection, Treatment, and Prevention. Fundamentals of Cancer Detection, Treatment, and Prevention
193
217
.
Stefania Crisci, Filomena Amitrano, Mariangela Saggese, Tommaso Muto, Sabrina Sarno, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Massimiliano Berretta & Raffaele Di Francia. (2019) Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina 55:8, pages 414.
Crossref
Crossref
Denis Smith, Eric Terrebonne, Magali Rouyer, Jean-Frédéric Blanc, Dominique Breilh, Stéphane Pedeboscq, Alise Le Monies, Coralie Lecomte, Régis Lassalle, Nicholas Moore & Annie Fourrier-Réglat. (2013) Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study. Fundamental & Clinical Pharmacology 27:1, pages 113-119.
Crossref
Crossref
Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, Kentaro Yamazaki, Taito Esaki, Keishi Yamashita, Mutsumi Fukunaga, Yasuhiro Miyake, Kenji Katsumata, Satoshi Kato, Taroh Satoh, Mitsuharu Ozeki, Eishi Baba, Shigemasa Yoshida, Narikazu Boku & Ichinosuke Hyodo. (2011) Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Medical Oncology 29:4, pages 2842-2848.
Crossref
Crossref
Ramazan Yildiz, Mustafa Benekli, Metin Ozkan, Necati Alkis, Veli Berk, Mehmet Ali Kaplan, Aydin Ciltas, Halit Karaca, Ayse Gok Durnali, Ugur Coskun, Mustafa Dikilitas, Alper Sevinc, Faysal Dane, Tarkan Yetisyigit, Gamze Gokoz Dogu & Suleyman Buyukberber. (2012) Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology 138:11, pages 1845-1852.
Crossref
Crossref
Jaafar Bennouna, Christophe Borg, Jean-Pierre Delord, Faress Husseini, Véronique Trillet-Lenoir, Roger Faroux, Eric François, Marc Ychou, François Goldwasser, Olivier Bouché, Helene Senellart, Sandrine Kraemer & Jean-Yves Douillard. (2012) Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. Clinical Colorectal Cancer 11:1, pages 38-44.
Crossref
Crossref
Keiichiro Ishibashi, Norimichi Okada, Toru Ishiguro, Kouki Kuwabara, Jun Sobajima, Tomonori Ohsawa, Kensuke Kumamoto, Norihiro Haga & Hideyuki Ishida. (2012) Second-line Chemotherapy with Bevacizumab for Refractory Colorectal Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 37:2, pages 176-182.
Crossref
Crossref
D. Spoerl & Andreas J. Bircher. 2012. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
579
607
.
S. Sogabe, Y. Komatsu, S. Yuki, T. Kusumi, K. Hatanaka, M. Nakamura, T. Kato, T. Miyagishima, A. Hosokawa, I. Iwanaga, Y. Sakata & M. Asaka. (2011) Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study. Japanese Journal of Clinical Oncology 41:4, pages 490-497.
Crossref
Crossref
Linda J.M. Oostendorp, Peep F. Stalmeier, Pieternel C. Pasker-de Jong, Winette T. Van der Graaf & Petronella B. Ottevanger. (2010) Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anti-Cancer Drugs 21:8, pages 749-758.
Crossref
Crossref
Keith I. Block. (2010) Cost Savings With Clinical Solutions: The Impact of Reforming Health and Health Care Economics With Integrative Therapies. Integrative Cancer Therapies 9:2, pages 129-135.
Crossref
Crossref